ONCAlert | Upfront Therapy for mRCC

GI Cancers VIEW MORE >>

The use of more aggressive frontline chemotherapy regimens plus biologics for the treatment of patients with meta-static colorectal cancer may be warranted based on mutational status, tumor sidedness, treatment goals, prognosis, and patient disposition, according to a presentation by Axel Grothey, MD, at the 14th Annual New Orleans Summer Cancer Meeting, held July 19 to 21, 2019, in Louisiana.

Latest JournalAll Journals >>

Copyright © TargetedOnc 2019 Intellisphere, LLC. All Rights Reserved.